Vascular tone, critical-care physiology, and clinical anticoagulation.
This topic groups related research questions. Shared biology does not make different peptides interchangeable, or establish a clinical benefit. Compare each paper’s population, preparation, and measured outcome.
Circulation & clotting: what the human evidence shows
Each peptide is sorted by the strongest kind of human study among its profile’s selected studies, and the row shows what that study found and who was studied. A higher tier means stronger evidence exists, not that the peptide works for circulation & clotting: the best trial may be small, negative or about a different condition. No doses.
Peptide
Strongest human evidence in our sources
FDA
Human safety data
FDA-approved medicine (4)Approved for the specific uses on its label, which may not be this goal.
VALIDATE-SWEDEHEART STEMI subgroup (2021) · Human randomized trial (prespecified subgroup) The composite of death, myocardial infarction, or major bleeding occurred in 12.5% versus 13.0%: hazard ratio 0.95 (95% CI 0.78–1.17). Limitation: The composite comparison was not statistically significant. Access route, accompanying antiplatelet treatment, and subgroup context limit generalization to every procedure. Studied: 3,005 patients with ST-elevation myocardial infarction in a prespecified VALIDATE-SWEDEHEART subgroup.
CORALreef Lipids: enlicitide versus placebo for 52 weeks (2026) · Human randomized phase 3 trial LDL cholesterol fell by about 57% with enlicitide and rose by 3% with placebo at week 24, a difference of about 56 percentage points. Reductions held at week 52, and non-HDL cholesterol, apolipoprotein B and lipoprotein(a) also fell more than with placebo. An earlier phase 2b trial reported reductions of up to about 61% after eight weeks. Limitation: The trial measured cholesterol levels, not heart attacks, strokes or deaths. Whether enlicitide lowers those events, as the injected PCSK9 antibodies have been shown to, is being tested in a separate outcomes trial that had not reported when this page was checked. Studied: 2,909 adults who had already had a major atherosclerotic event, or were at risk of a first one, with LDL cholesterol above set thresholds…
CONFIRM (2021) · Human randomized trial Verified hepatorenal-syndrome reversal occurred in 32% versus 17%. At 90 days, deaths occurred in 51% versus 45%; respiratory-disorder deaths occurred in 11% versus 2%. Limitation: Improvement in the specified kidney-function endpoint did not demonstrate a survival advantage. Serious respiratory harms are essential context for the result. Studied: 300 adults with type 1 hepatorenal syndrome, randomized 199 to terlipressin and 101 to placebo.
VASST (2008) · Human randomized trial Mortality at 28 days was 35.4% versus 39.3% (P=0.26). At 90 days it was 43.9% versus 49.6% (P=0.11). Neither overall comparison was statistically significant. Limitation: An apparent subgroup difference in less severe shock does not establish overall mortality superiority. Critical-care treatment context limits application to other populations. Studied: 778 patients with septic shock who were already receiving vasopressors.
FDA-approved
FDA label
Randomized human trials (2)At least one randomized or placebo-controlled trial, which may be small, negative or about another condition.
PACAP-38 challenge after eptinezumab or placebo (2025) · Human randomized provocation study Migraine occurred in 10 of 19 versus 12 of 19 participants; the difference was not significant (P=0.74). Headache was common after the challenge. Limitation: The small provocation study does not establish therapeutic benefit of PACAP-38 or a definitive clinical prevention strategy. Studied: 38 participants with migraine without aura, 19 in each pretreatment group.
TESICO aviptadil trial (2023) · Human randomized trial The primary outcome was not significantly better with aviptadil: odds ratio 1.11, 95% CI 0.80–1.55, P=0.54. Mortality was also not significantly different. Limitation: This negative comparison should remain visible. It neither proves benefit nor answers every proposed chronic use of VIP. Studied: 461 people with COVID-19-associated respiratory failure.
Not approved
Trials only
Animal and lab studies only (1)No human study in our sources.
B7-33 is a short, lab-designed peptide built from part of relaxin-2, a natural hormone best known for its role in pregnancy. It was designed to keep relaxin's anti-scarring and blood-vessel effects in a smaller molecule. Its evidence comes from animal and cell studies, not people.
Bivalirudin is a direct thrombin-inhibitor peptide used in procedural anticoagulation. The featured analysis examined patients with ST-elevation myocardial infarction undergoing coronary intervention.
Enlicitide is a ring-shaped peptide designed to block PCSK9, the same target as the antibody medicines Repatha and Praluent, but taken as a daily pill instead of an injection. The FDA approved it in July 2026 under the brand name Lipfendra to lower LDL cholesterol in adults with high cholesterol.
PACAP-38 is a signaling peptide used in migraine-provocation research. The selected clinical study tested whether prior CGRP-pathway treatment prevented a migraine response to a PACAP-38 challenge.
Terlipressin is a vasopressin-related medicine used in a specific hepatorenal-syndrome setting. Its kidney-function results must be considered with the risk of serious respiratory complications.
Arginine vasopressin is a nine-residue hormone involved in water balance and vascular tone. VASST compared vasopressin with norepinephrine in septic shock.
Vasoactive intestinal peptide participates in vascular and immune signaling. A large trial of intravenous aviptadil in COVID-19 respiratory failure did not show a significant improvement in its primary outcome.
We check sellers’ lab reports with the testing labs themselves.
So far 89 of the 105 lab reports we looked up matched the testing lab’s own record, and 12 did not.
A free account shows which sellers, report by report, plus daily prices, deals, Ask PepsRadar and alerts. If you want it, the PepsRadar Weekly brings new research and FDA news once a week. No dosing advice.